Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Disc Medicine, Inc.

2024-Q3 EPS reported -$2.98

Completed successful end-of-Phase 2 meeting with FDA for bitopertin in EPP, reaching alignment on all proposed study parameters with potential for accelerated approval.
Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in NDD-CKD patients with anemia at ASN Kidney Week 2024.
Ended Q3 2024 with $487M cash; closed $200M non-dilutive debt financing with Hercules Capital in November 2024.
Net loss was $26.6M for Q3 2024, compared to $14.1M for same period in 2023.
Appointed Steve Caffé as Chief Regulatory Officer and Rahul Kaushik as Chief Technical Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.